Basaglar ® (insulin glargine injection)

100 units/mL

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

Do patients on Basaglar® (insulin glargine) achieve an HbA1c of <7%?

In patients with type 1 diabetes treated with Basaglar, 34.5% achieved an HbA1c <7% at 24 weeks while 48.8% with type 2 diabetes achieved an HbA1c <7%. The percentages were similar to those achieved with comparator insulin glargine 100 units/mL products.

US_cFAQ_BIV019_LESS_THAN_7_HBA1C
US_cFAQ_BIV019_LESS_THAN_7_HBA1C
en-US

Basaglar Clinical Studies: Type 1 or Type 2 Diabetes

Adult patients with inadequately controlled type 1 diabetes participated in a 24-week, open‑label, active-controlled study with a 28-week extension to evaluate the glucose lowering effect of once-daily Basaglar® (insulin glargine) 100 units/mL compared with that of once-daily administration of another insulin glargine 100 units/mL product or a non-US-approved insulin glargine 100 units/mL product, both in combination with mealtime insulin lispro.1

Adult patients with type 2 diabetes participated in a double-blind, active-controlled study to evaluate the glucose lowering effect of once-daily Basaglar plus oral antihyperglycemic medications (OAMs) compared with that of another insulin glargine 100 units/mL product or a non‑US‑approved insulin glargine 100 units/mL product administered once daily along with OAMs. Patients were

  • insulin naïve (~60%) and had failed to achieve adequate glycemic control on at least 2 OAMs, or
  • already on another insulin glargine 100 units/mL product or a non‑US‑approved insulin glargine 100 units/mL product along with at least 2 OAMs with adequate or inadequate glycemic control (~40%).1

HbA1c Less Than 7%

At 24 weeks, the percentage of patients who achieved a glycated hemoglobin (HbA1c) of <7% was similar between treatment groups (Achievement of HbA1c Less Than 7% at 24 Weeks in Phase 3 Clinical Studies of Basaglar).1

Achievement of HbA1c Less Than 7% at 24 Weeks in Phase 3 Clinical Studies of Basaglar1

HbA1c

Type 1 Diabetes

Type 2 Diabetes

Basaglar + Insulin Lispro
(n=268)a

Comparator Insulin Glargine 100 Units/mL Productsb + Insulin Lispro
(n=267)

Basaglar + OAMs
(n=376)c

Comparator Insulin Glargine 100 Units/mL Productsb + OAMs
(n=380)

Percentage of patients achieving HbA1c <7%d

34.5

32.2

48.8

52.5

Abbreviations: Basaglar = Basaglar® (insulin glargine) 100 units/mL; HbA1c = glycated hemoglobin; OAMs = oral antihyperglycemic medications.

aIncludes 1 patient randomized to the Basaglar treatment group who was not included in the full analysis set.

bAnother insulin glargine 100 units/mL product and a non-US-approved insulin glargine 100 units/mL product.

cA total of 3 patients randomized to the Basaglar treatment group did not receive study drug and were not included in the full analysis set.

dResults were calculated based on the number of patients in the full analysis set using their last observed postbaseline value of HbA1c. Observed HbA1c data at 24 weeks were available from 256 patients (95.5%) in the Basaglar treatment group and 258 patients (96.6%) in the comparator insulin glargine 100 units/mL treatment group in patients with type 1 diabetes and from 331 patients (88%) in the Basaglar treatment group and 329 patients (87%) in the comparator insulin glargine 100 units/mL treatment group in patients with type 2 diabetes.

Reference

1Basaglar [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.

Date of Last Review: October 28, 2021


Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 9am - 7pm EST

Or you can

Chat with us

Chat with us

Submit a Request

Visit Us @LillyMedical